Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]
It has been announced by the International Strategic Cancer Alliance that a Dutch university that intends to launch global trials has purchased the Combidex technology. Combidex is a scan contrast that periodically gets discussed among prostate cancer survivors, but it has not been available for a few years. It is an injectable nanoparticle fluid (contrast) [...]
The commonly used serum (blood) marker for inflammation is C-reactive protein (CRP). It is believed that CRP has a prognostic impact for men with metastatic prostate cancer (MPC) (advanced prostate cancer). The researchers conducted a meta-analysis to quantitate its prognostic impact. They conducted asystematic review to identify publications and presentations exploring the association of baseline [...]
Today’s New York Times Science Times section had a very interesting article written by Tara Parker-Poe about Male breast cancer. As her opening line of the article went, “Breast cancer is not always pink.” She wrote about a photography series recently mounted that feature the faces and scars of men with breast cancer. The photos [...]
The best way to understand your PSA kinetics, especially its changes, is to be able to visualize them on a graph. This allows you to understand significant changes in our PSA earlier on than you might otherwise perceive them. Any man whether diagnosed with prostate cancer or not should be recording their PSA scores and [...]